Patients with stage Ⅲ N2 non-small cell lung cancer (NSCLC) are more than one third of all NSCLC patients.The 5-year survival rate of them is approximately 15%
Objective: Currently, only a limited numbers of tumor markers for non small lung cancer (NSCLC) diagnosis, new biomarker, such as serum autoantibodies may impro